GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Institutional Ownership

Cellectis (XPAR:ALCLS) Institutional Ownership : 1.83% (As of May. 03, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Cellectis Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cellectis's institutional ownership is 1.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cellectis's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cellectis's Float Percentage Of Total Shares Outstanding is 80.20%.


Cellectis Institutional Ownership Historical Data

The historical data trend for Cellectis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Institutional Ownership Chart

Cellectis Historical Data

The historical data trend for Cellectis can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 2.84 2.44 2.41 2.28 2.06 1.79 2.78 1.95 1.83 1.83

Cellectis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cellectis Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines